DBV Technologies SA – (DBVT) Downgraded to “Hold” at Zacks Investment Research

DBV Technologies SA – (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

Other research analysts also recently issued research reports about the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $47.00 price target on shares of DBV Technologies SA – in a research note on Thursday. Societe Generale upgraded shares of DBV Technologies SA – from a “hold” rating to a “buy” rating in a research note on Thursday. Natixis upgraded shares of DBV Technologies SA – from a “neutral” rating to a “buy” rating in a research note on Friday, February 17th. Finally, Leerink Swann reiterated an “outperform” rating on shares of DBV Technologies SA – in a research note on Wednesday, March 15th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. DBV Technologies SA – currently has a consensus rating of “Buy” and an average price target of $46.50.

Analyst Recommendations for DBV Technologies SA - (NASDAQ:DBVT)

DBV Technologies SA – (NASDAQ:DBVT) traded up 1.55% during mid-day trading on Monday, hitting $35.42. 103,040 shares of the stock were exchanged. The firm’s market cap is $1.63 billion. DBV Technologies SA – has a 52-week low of $27.02 and a 52-week high of $37.98. The company has a 50 day moving average price of $35.33 and a 200 day moving average price of $35.61.

Your IP Address:

Several hedge funds have recently modified their holdings of the company. Perceptive Advisors LLC bought a new stake in shares of DBV Technologies SA – during the fourth quarter valued at $21,452,000. Arrowpoint Asset Management LLC increased its stake in shares of DBV Technologies SA – by 12.6% in the fourth quarter. Arrowpoint Asset Management LLC now owns 832,990 shares of the company’s stock valued at $29,263,000 after buying an additional 93,255 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in shares of DBV Technologies SA – by 0.6% in the third quarter. TimesSquare Capital Management LLC now owns 990,503 shares of the company’s stock valued at $35,985,000 after buying an additional 5,950 shares in the last quarter. Sphera Funds Management LTD. increased its stake in shares of DBV Technologies SA – by 30.4% in the third quarter. Sphera Funds Management LTD. now owns 79,058 shares of the company’s stock valued at $2,872,000 after buying an additional 18,447 shares in the last quarter. Finally, Baker BROS. Advisors LP bought a new stake in shares of DBV Technologies SA – during the third quarter valued at $200,162,000. Institutional investors and hedge funds own 48.96% of the company’s stock.

About DBV Technologies SA –

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

5 Day Chart for NASDAQ:DBVT

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply